DK1459766T3 - Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner - Google Patents
Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vaccinerInfo
- Publication number
- DK1459766T3 DK1459766T3 DK04014973T DK04014973T DK1459766T3 DK 1459766 T3 DK1459766 T3 DK 1459766T3 DK 04014973 T DK04014973 T DK 04014973T DK 04014973 T DK04014973 T DK 04014973T DK 1459766 T3 DK1459766 T3 DK 1459766T3
- Authority
- DK
- Denmark
- Prior art keywords
- polynucleotide
- immune responses
- based vaccines
- adjuvant compositions
- boost immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12634099P | 1999-03-26 | 1999-03-26 | |
PCT/US2000/008282 WO2000057917A2 (en) | 1999-03-26 | 2000-03-24 | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1459766T3 true DK1459766T3 (da) | 2008-10-13 |
Family
ID=22424291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04014973T DK1459766T3 (da) | 1999-03-26 | 2000-03-24 | Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner |
Country Status (10)
Country | Link |
---|---|
US (7) | US6586409B1 (da) |
EP (2) | EP1955709B1 (da) |
JP (2) | JP4800485B2 (da) |
AT (3) | ATE549032T1 (da) |
CA (1) | CA2365416C (da) |
DE (2) | DE60039198D1 (da) |
DK (1) | DK1459766T3 (da) |
ES (1) | ES2308069T3 (da) |
HK (1) | HK1121382A1 (da) |
WO (1) | WO2000057917A2 (da) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
JP2001523480A (ja) * | 1997-11-20 | 2001-11-27 | バイカル インコーポレイテッド | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 |
EP1955709B1 (en) | 1999-03-26 | 2012-03-14 | Vical Incorporated | Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines |
US7078388B2 (en) * | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US6875748B2 (en) * | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
US20030162733A1 (en) * | 2000-11-27 | 2003-08-28 | Haynes Joel R. | Nucleic acid adjuvants |
GB0210538D0 (en) * | 2002-05-08 | 2002-06-19 | Univ London | Lipids and gene delivery |
US7598421B2 (en) | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
AU2003293195A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
EP2311848B1 (en) | 2002-12-23 | 2013-07-03 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
AU2003293196A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
US7504243B2 (en) | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
CA2566355C (en) * | 2004-05-18 | 2014-04-15 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
NZ552583A (en) | 2004-06-15 | 2009-09-25 | New York Blood Ct Inc | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
WO2006060723A2 (en) * | 2004-12-03 | 2006-06-08 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
AU2006203985A1 (en) * | 2005-01-05 | 2006-07-13 | Philadelphia Health And Education Corporation | Delivery vehicles, bioactive substances and viral vaccines |
CN101180312A (zh) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
EP1877087B1 (en) | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
EP2532386A3 (en) | 2005-07-22 | 2013-02-20 | TomoTherapy, Inc. | System for delivering radiation therapy to a moving region of interest |
JP2009502251A (ja) | 2005-07-22 | 2009-01-29 | トモセラピー・インコーポレーテッド | 放射線治療システムによって送達された線量を評価するシステム及び方法 |
KR20080039916A (ko) | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | 움직이는 관심 영역에 방사선 치료를 시행하는 시스템 및방법 |
WO2007014108A2 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treament plan |
US9731148B2 (en) | 2005-07-23 | 2017-08-15 | Tomotherapy Incorporated | Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch |
DK2368572T3 (da) | 2005-11-04 | 2020-05-25 | Seqirus Uk Ltd | Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur |
WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
EP2478916B1 (en) | 2006-01-27 | 2020-04-01 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
EP2382987A1 (en) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Storage of influenza vaccines without refrigeration |
WO2007126825A2 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
AU2007297178B2 (en) | 2006-09-11 | 2014-07-24 | Novartis Ag | Making influenza virus vaccines without using eggs |
WO2008127450A2 (en) * | 2006-12-04 | 2008-10-23 | Vical Incorporated | Linear expression cassette vaccines |
CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
CA2684923C (en) | 2007-05-02 | 2015-01-06 | Merial Limited | Dna plasmids having improved expression and stability |
US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
EP2167480A2 (en) * | 2007-05-23 | 2010-03-31 | Vical Incorporated | Cationic lipids compositions and methods for enhancing immune responses to vaccines |
US20090004203A1 (en) * | 2007-05-29 | 2009-01-01 | Vical Incorporated | Methods of treating measles infectious disease in mammals |
NZ582595A (en) | 2007-06-27 | 2012-07-27 | Novartis Ag | Low-additive influenza vaccines |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
ES2712505T3 (es) | 2008-04-17 | 2019-05-13 | Pds Biotechnology Corp | Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos |
RU2570732C9 (ru) * | 2009-05-14 | 2016-09-10 | Байер Интеллектуэль Проперти Гмбх | Усиленный иммунный ответ у видов птиц |
SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
WO2011149564A1 (en) | 2010-05-28 | 2011-12-01 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
BR112013002993A2 (pt) | 2010-08-09 | 2018-01-30 | Cyvax Inc | métodos e composições para prevenção de uma condição |
DK2654785T3 (da) | 2010-12-22 | 2019-06-24 | Bayer Ip Gmbh | Forøget immunrespons hos kvægracer |
HUE043879T2 (hu) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | RSV-immunizálási rend |
US20140248314A1 (en) | 2011-05-13 | 2014-09-04 | Novartis Ag | Pre-fusion rsv f antigens |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
WO2013106558A1 (en) * | 2012-01-10 | 2013-07-18 | Merial Limited | Lipid based adjuvants for dna - plasmid vaccines |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
JP2015530413A (ja) | 2012-09-21 | 2015-10-15 | ベデュ−アッド,フランク | 改良されたワクチン組成物および使用方法 |
US9443633B2 (en) | 2013-02-26 | 2016-09-13 | Accuray Incorporated | Electromagnetically actuated multi-leaf collimator |
CA2940794C (en) | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
TW201718001A (zh) | 2015-07-31 | 2017-06-01 | 拜耳動物保健有限公司 | 豬物種中增強之免疫反應 |
WO2017083820A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
EP3386593A4 (en) | 2015-12-09 | 2019-07-24 | Admedus Vaccines Pty Ltd | IMMUNOMODULATING COMPOSITION FOR TREATMENT |
CN105483076B (zh) * | 2015-12-23 | 2019-01-25 | 中国科学院生物物理研究所 | 一种脂肪体的制备方法及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US20030186913A1 (en) | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
IL113817A (en) | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP1489184A1 (en) | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP0863749A2 (en) | 1995-11-30 | 1998-09-16 | Vical Incorporated | Complex cationic lipids |
US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US6235310B1 (en) * | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
JP2001523480A (ja) * | 1997-11-20 | 2001-11-27 | バイカル インコーポレイテッド | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 |
EP1955709B1 (en) * | 1999-03-26 | 2012-03-14 | Vical Incorporated | Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines |
US6696424B1 (en) | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
US6875748B2 (en) | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
US20030091544A1 (en) | 2001-03-13 | 2003-05-15 | Vical Incorporated | Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases |
EP1470869B1 (en) | 2002-01-28 | 2011-03-09 | JFE Steel Corporation | Method for producing coated steel sheet |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
EP2311848B1 (en) | 2002-12-23 | 2013-07-03 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
AU2003293195A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
AU2003293196A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
-
2000
- 2000-03-24 EP EP08006254A patent/EP1955709B1/en not_active Expired - Lifetime
- 2000-03-24 WO PCT/US2000/008282 patent/WO2000057917A2/en active Search and Examination
- 2000-03-24 EP EP00919777A patent/EP1165140B1/en not_active Expired - Lifetime
- 2000-03-24 AT AT08006254T patent/ATE549032T1/de active
- 2000-03-24 DK DK04014973T patent/DK1459766T3/da active
- 2000-03-24 DE DE60039198T patent/DE60039198D1/de not_active Expired - Fee Related
- 2000-03-24 AT AT00919777T patent/ATE272410T1/de not_active IP Right Cessation
- 2000-03-24 JP JP2000607666A patent/JP4800485B2/ja not_active Expired - Fee Related
- 2000-03-24 DE DE60012711T patent/DE60012711T2/de not_active Expired - Lifetime
- 2000-03-24 ES ES04014973T patent/ES2308069T3/es not_active Expired - Lifetime
- 2000-03-24 US US09/534,943 patent/US6586409B1/en not_active Expired - Lifetime
- 2000-03-24 AT AT04014973T patent/ATE397942T1/de active
- 2000-03-24 CA CA2365416A patent/CA2365416C/en not_active Expired - Fee Related
-
2003
- 2003-03-19 US US10/391,216 patent/US7582613B2/en not_active Expired - Fee Related
-
2007
- 2007-03-23 JP JP2007075889A patent/JP2007176954A/ja not_active Withdrawn
- 2007-08-17 US US11/889,980 patent/US20080213306A1/en not_active Abandoned
- 2007-08-17 US US11/889,977 patent/US20080145387A1/en not_active Abandoned
-
2009
- 2009-02-11 HK HK09101261.1A patent/HK1121382A1/xx not_active IP Right Cessation
-
2011
- 2011-02-18 US US13/031,064 patent/US8415317B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/802,567 patent/US20130295139A1/en not_active Abandoned
- 2013-03-13 US US13/802,535 patent/US20140065189A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080145387A1 (en) | 2008-06-19 |
US20140065189A1 (en) | 2014-03-06 |
HK1121382A1 (en) | 2009-04-24 |
EP1955709A2 (en) | 2008-08-13 |
ATE549032T1 (de) | 2012-03-15 |
EP1955709A3 (en) | 2008-08-20 |
US20030191082A1 (en) | 2003-10-09 |
JP2007176954A (ja) | 2007-07-12 |
US20080213306A1 (en) | 2008-09-04 |
JP4800485B2 (ja) | 2011-10-26 |
US7582613B2 (en) | 2009-09-01 |
WO2000057917A2 (en) | 2000-10-05 |
DE60012711T2 (de) | 2005-08-18 |
EP1165140A2 (en) | 2002-01-02 |
DE60012711D1 (de) | 2004-09-09 |
ES2308069T3 (es) | 2008-12-01 |
US6586409B1 (en) | 2003-07-01 |
CA2365416C (en) | 2011-06-14 |
EP1165140B1 (en) | 2004-08-04 |
JP2002540173A (ja) | 2002-11-26 |
EP1955709B1 (en) | 2012-03-14 |
US20110165197A1 (en) | 2011-07-07 |
US20130295139A1 (en) | 2013-11-07 |
CA2365416A1 (en) | 2000-10-05 |
DE60039198D1 (de) | 2008-07-24 |
ATE272410T1 (de) | 2004-08-15 |
WO2000057917A3 (en) | 2001-01-04 |
US8415317B2 (en) | 2013-04-09 |
ATE397942T1 (de) | 2008-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1459766T3 (da) | Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner | |
NO20023829D0 (no) | Proteosom influensavaksine | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
DK1104306T3 (da) | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf | |
DK1147117T3 (da) | Immunologiske adjuvansforbindelser | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
GB2386072A (en) | Novel vaccine | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
DK1259259T3 (da) | Mucosal adjuvansformulering | |
AU2001284354A1 (en) | Immunological adjuvant compounds, compositions, and methods of use thereof | |
ATE284613T1 (de) | Polynukleotid-impfstoff-formulierungen | |
DE69637435D1 (de) | Saponin-zusammensetzungen und deren verwendung | |
ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
DK1227840T3 (da) | Adjuverede, genetiske vacciner | |
DE69942161D1 (de) | Genetische Adjuvanz-Impfstoffe | |
EP1721618A3 (en) | Proteosome influenza vaccine composition |